Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailGoldman Sachs raises target on Eli Lilly: Here's whyChris Shibutani, Goldman Sachs anlayst, joins 'Squawk on the Street' to discuss what gives the analyst the confidence Eli Lilly and Novo Nordisk can continue to perform, what happens to the anti-obesity industry in 2030, and how the market will evolve.
Persons:
Goldman Sachs, Eli Lilly, Here's, Chris Shibutani, Goldman Sachs anlayst
Organizations:
Novo Nordisk